Sandipkumar S. Kapadia
Director of Finance/CFO at HARMONY BIOSCIENCES HOLDINGS, INC.
Net worth: - $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 6 years |
| Patrick Amstutz | M | 49 |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 20 years |
| Thomas Woiwode | M | 52 |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 6 years |
| Michael Tobias Stumpp | M | 52 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 20 years |
| Edgar Cale | M | 60 | 5 years | |
| William Burns | M | 76 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 7 years |
| Jeffrey Dayno | M | 66 | 7 years | |
| Chahra Khaoua Epouse Louafi | F | 53 |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland.
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Jerome B. Durso | M | 56 | 7 years | |
| Michael Vasconcelles | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 years |
| Maxine Gowen | M | 66 | 3 years | |
| Paul Carter | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 years |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Steven Holtzman | M | 70 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 10 years |
| William Chou | M | 51 | 2 years | |
| Murray Stewart | M | 63 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 3 years |
| Vito Palombella | M | 61 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 4 years |
| James M. Wilson | M | - | 7 years | |
| Derrell Porter | M | 53 | 3 years | |
| Linda Szyper | F | 58 | 3 years | |
| Jeffrey Aronin | M | 56 | 7 years | |
| Jared M. Freedberg | M | 55 | 3 years | |
| R. Graf | M | 59 | 4 years | |
| Daniel Steiner | M | - | 13 years | |
| Daniel Carey Cazel Hood | M | 51 |
Intercept Pharma Europe Ltd.
 Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The private company is based in Bristol, UK. | - |
| Jeffrey Dierks | M | 52 | 7 years | |
| Ulrich Christian | M | - | 3 years | |
| Sharon Goldbach | F | - | - | |
| Dominik Höchli | M | 57 | 3 years | |
| Kathleen Borthwick | F | 48 | 3 years | |
| Lisa Bright | F | 56 |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The private company is based in Bristol, UK. | 10 years |
| Kumar Budur | M | 53 | - | |
| Athena Countouriotis | M | 52 | 4 years | |
| Gary Sender | M | 62 | 4 years | |
| Stuart M. Henderson | M | - | 3 years | |
| Saqib Islam | M | 54 | 5 years | |
| Andreas Emmenegger | M | 58 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 17 years |
| Seth D. Lewis | M | - | 5 years | |
| Agnete Brunsvik Fredriksen | M | 47 | 3 years | |
| Juan Sabater | M | 59 | 7 years | |
| Gwen A. Fyfe | M | 72 |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The private company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | 5 years |
| Jack Nielsen | M | 60 | 7 years | |
| Andreas Wicki | M | 64 | 7 years | |
| Peter Anastasiou | M | 53 | 1 years | |
| Antonio Gracias | M | 53 | 7 years | |
| Cate McCanless | F | - | - | |
| Renate Gloggner | F | - | 3 years | |
| Alexander Zürcher | M | - | 2 years | |
| Philippe Legenne | M | - | 4 years | |
| Luis Sanay | M | - | 2 years | |
| Michael Pitzner | M | - | 2 years | |
| Clarence Machado | M | 60 |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | - |
| Dolan Sondhi | M | 53 | 1 years | |
| Mark Forman | M | 60 | 3 years | |
| Andrew Serafin | M | 49 | 7 years | |
| Audrey Murphy | F | - | - | |
| Jørgen Søberg Petersen | M | - |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | - |
| Andrea Campanile | F | - | - | |
| David Bradshaw | M | 62 | - | |
| Brant Schofield | M | - |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 8 years |
| Baris Arican | M | - | 2 years | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Mark Pruzanski | M | 56 |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The private company is based in Bristol, UK. | - |
| Alex Fotopoulos | M | 55 | 5 years | |
| Tricia Glover | F | - | - | |
| Linda M. Richardson | F | 60 | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bruce Goldsmith | M | 58 | 2 years | |
| John Jacobs | M | 57 | 6 years | |
| Jonathan Silverstein | M | 57 | 7 years | |
| Klaus Veitinger | M | 62 | 4 years | |
| Wouter Joustra | M | 35 | 1 years | |
| Bryan Ball | M | 54 | 1 years | |
| Bryan Yoon | M | 46 | 4 years | |
| Nancy Miller-Rich | F | 65 | 5 years | |
| Eric L. Motley | M | 51 | 1 years | |
| Michael Kamarck | M | 73 | 1 years | |
| Mark Vignola | M | 47 | 4 years | |
| Scott Applebaum | M | 57 | - | |
| Keith Gottesdiener | M | 70 | 7 years | |
| Göran Albert Ando | M | 75 | 10 years | |
| Daniel Bradbury | M | 62 | 7 years | |
| Tadataka Yamada | M | 77 | 4 years | |
| Patrick Heron | M | 53 | 3 years | |
| Liam Ratcliffe | M | 60 | 3 years | |
| Patrick Malloy | M | - | - | |
| Ryan Sullivan | M | 48 | 2 years | |
| Nicolas Leupin | M | 50 | 4 years | |
| Eliseo Salinas | M | 69 | 1 years | |
| Desiree Luthman | M | 65 | 3 years | |
| David Ford | M | 56 | 6 years | |
| Simona King | F | 52 | 2 years | |
| William Lee | M | 69 | 13 years | |
| Jason A. Campagna | M | 54 | 2 years | |
| Gary Romano | M | 63 | 2 years | |
| Gwendolyn Fisher | F | - | 2 years | |
| Sarah Holland | F | 61 | 2 years | |
| Brian Burkavage | M | - | 1 years | |
| Monika Tornsen | F | 45 | 1 years | |
| Joseph Vazzano | M | 40 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 74.00% |
| Switzerland | 34 | 34.00% |
| United Kingdom | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Sandipkumar S. Kapadia
- Personal Network
